Role of the Mdm2 SNIP 309 Polymorphism in Gastric Mucosal Morphologic Patterns of Patients with Helicobacter pylori Associated Gastritis |
Tongtawee, Taweesak
(Department of Surgery, Suranaree University of Technology)
Dechsukhum, Chavaboon (Pathological Unit, Institute of Medicine, Suranaree University of Technology) Leeanansaksiri, Wilairat (Institute of Science, Suranaree University of Technology) Kaewpitoon, Soraya (Family Medicine and Community Medicine, Suranaree University of Technology) Kaewpitoon, Natthawut (Parasite Research Unit, Suranaree University of Technology) Loyd, Ryan A (Family Medicine and Community Medicine, Suranaree University of Technology) Matrakool, Likit (Department of Surgery, Suranaree University of Technology) Panpimanmas, Sukij (Department of Surgery, Suranaree University of Technology) |
1 | Bond GL, Hu W, Levine AJ, et al (2005). MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets, 5, 3-8. DOI |
2 | Gono K, Obi T, Yamaguchi M, et al (2004). Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt, 9, 568-77. DOI |
3 | Gurova KV, Hill JE, Guo C, et al (2005). Small molecules that reactivate p53 in renal cell carcinoma reveals a nf-kappab-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA., 102, 17448-53. DOI |
4 | Haupt Y, Maya R, et al (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9. DOI |
5 | Honda R, Tanaka H, et al (1997). Oncoprotein MDM2 is an ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters, 420, 25-7. DOI |
6 | Kentaro S, Jan T, Ernst JK, et al (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64, 1353-67. DOI |
7 | Komarova EA, Krivokrysenko V, Wang K, et al (2005). P53 is a suppressor of inflammatory response in mice. FASEB J, 19, 1030-2. DOI |
8 | Kubbutat MH, Jones SN, et al (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303. DOI |
9 | MF Dixon, RM Genta JH, Harley et al (1996). "Classification and grading of gastritis. The Updated Sydney system. Am J Surgical Pathol, 20, 1161-81. |
10 | Momand J, Zambetti GP, et al (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237- 45. DOI |
11 | Moradi MT, Salehi Z, Aminian K, et al (2014). Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population. Asian Pac J Cancer Prev, 15, 7413-7. DOI |
12 | O'Prey J, Crighton D, Martin AG, et al (2010). P53-mediated induction of noxa and p53aip1 requires nfkappab. Cell Cycle, 9, 947-52. DOI |
13 | Picksley SM, Lane DP et al (1993).The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays, 15, 689-90. DOI |
14 | Yagi K, Nakamura A, Sekine A, et al (2002). Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy, 34, 376-81. DOI |
15 | Taweesak T, Soraya K, Natthawut K, et al (2015). Correlation between gastric mucosal morphologic patterns and histopathological severity of helicobacter pylori associated gastritis using conventional narrow band imaging gastroscopy. Bio Med Res Int, 7, 42-8. |
16 | Tergaonkar V, Pando M, Vafa O, et al (2002). P53 stabilization is decreased upon nf kappa b activation: A role for nfkappab in acquisition of resistance to chemotherapy. Cancer Cell, 1, 493-503. DOI |
17 | Wang X, Yang J, Ho B, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9. |